ATE206914T1 - Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen - Google Patents

Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen

Info

Publication number
ATE206914T1
ATE206914T1 AT96308340T AT96308340T ATE206914T1 AT E206914 T1 ATE206914 T1 AT E206914T1 AT 96308340 T AT96308340 T AT 96308340T AT 96308340 T AT96308340 T AT 96308340T AT E206914 T1 ATE206914 T1 AT E206914T1
Authority
AT
Austria
Prior art keywords
ursolic acid
produce
medicinal product
suppressing metastasis
metastasis
Prior art date
Application number
AT96308340T
Other languages
English (en)
Inventor
Hiromichi Ishikawa
Satoshi Nishimuro
Tomoko Kojima
Mitsuru Hirota
Original Assignee
Japan Chem Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Chem Res filed Critical Japan Chem Res
Application granted granted Critical
Publication of ATE206914T1 publication Critical patent/ATE206914T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96308340T 1995-11-16 1996-11-15 Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen ATE206914T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7323710A JP3041232B2 (ja) 1995-11-16 1995-11-16 癌転移抑制剤

Publications (1)

Publication Number Publication Date
ATE206914T1 true ATE206914T1 (de) 2001-11-15

Family

ID=18157744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96308340T ATE206914T1 (de) 1995-11-16 1996-11-15 Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen

Country Status (7)

Country Link
US (1) US5985924A (de)
EP (1) EP0774255B1 (de)
JP (1) JP3041232B2 (de)
KR (1) KR100424503B1 (de)
CN (1) CN1073843C (de)
AT (1) ATE206914T1 (de)
DE (1) DE69615984T2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775686B1 (fr) * 1998-03-09 2006-07-28 Pascal Commenil Exploitation industrielle et commerciale des lipides cuticulaires de la baie de raisin en pharmacologie et cosmetologie
DE60102402T2 (de) * 2000-02-10 2005-03-10 Loders Croklaan B.V. Fettmischungen mit Kristallmodifikatoren
WO2002009719A1 (fr) * 2000-07-31 2002-02-07 The Nisshin Oillio, Ltd. Agents antitumoraux
WO2002009720A1 (en) * 2000-07-31 2002-02-07 University Of Virginia Patent Foundation Inhibitors of dna polymerase sigma
AU2002222753A1 (en) * 2000-12-15 2002-06-24 Naturalendo Tech Co., Ltd. Compositions for inducing secretion of insulin-like growth factor-1
US6979470B2 (en) * 2001-07-17 2005-12-27 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
CA2486704A1 (en) * 2002-05-24 2003-12-04 Greystone Medical Group, Inc. Anti-cancer formulation
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
US20070249711A1 (en) 2003-10-10 2007-10-25 Wonrack Choi Triterpene Compounds which are Effective on Improvement of Brain Function
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
WO2014022772A1 (en) 2012-08-03 2014-02-06 University Of Iowa Research Foundation Tomatidine, analogs thereof, compositions comprising same, and uses for same
WO2012170546A1 (en) 2011-06-06 2012-12-13 University Of Iowa Research Foundation Methods of inhibiting muscle atrophy
WO2011146768A1 (en) * 2010-05-20 2011-11-24 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2014008361A2 (en) * 2012-07-05 2014-01-09 Nutramax Laboratories, Inc. Compositions comprising a sulforaphane or a sulforaphane precursor and milk thistle extract or powder
JP6211380B2 (ja) * 2012-10-17 2017-10-11 丸善製薬株式会社 Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤
KR102155125B1 (ko) * 2015-07-17 2020-09-11 경희대학교 산학협력단 악성 중피종 예방 또는 치료용 조성물
CN105534991A (zh) * 2015-12-24 2016-05-04 上海交通大学医学院 五环三萜类化合物在制备usp7抑制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE707409A (de) * 1967-12-01 1968-04-16
JPS6439973A (en) * 1987-08-06 1989-02-10 Taiyo Kagaku Kk Drink composition
JPH03287530A (ja) * 1990-03-31 1991-12-18 Snow Brand Milk Prod Co Ltd 免疫抑制剤
US5519008A (en) * 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
JPH0748250A (ja) * 1993-06-04 1995-02-21 Sekisui Chem Co Ltd 眠気防止用テープ
US5643884A (en) * 1993-08-09 1997-07-01 Glycomed Incorporated Lupane triterpenoid derivatives

Also Published As

Publication number Publication date
EP0774255A1 (de) 1997-05-21
KR970025615A (ko) 1997-06-24
DE69615984D1 (de) 2001-11-22
KR100424503B1 (ko) 2004-06-04
US5985924A (en) 1999-11-16
JPH09143076A (ja) 1997-06-03
EP0774255B1 (de) 2001-10-17
CN1073843C (zh) 2001-10-31
CN1157716A (zh) 1997-08-27
JP3041232B2 (ja) 2000-05-15
DE69615984T2 (de) 2002-07-04

Similar Documents

Publication Publication Date Title
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE130758T1 (de) Arzneimittel zur intranasalen verabreichung, die ketorolac r enthalten.
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
BR9606604A (pt) Composto e método para a fabricação de um medicamento ou para aperfeiçoar o transporte de uma droga ou outro ativo para cruzar as membranas lipidicas no corpo ou assegurar a ação
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE135577T1 (de) Verwendung von buspiron zur herstellung eines pharmazeutischen präparats zur behandlung der alkoholsucht
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
DE68926115D1 (de) Verfahren zur behandlung von akne
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
ATE135573T1 (de) Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
HUP0103864A2 (hu) 3-(1H-4-Imidazolimetil)-indan-5-ol alkalmazása intraspinálisan beadható gyógyszerkészítmények előállítására
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties